Evidence Hub

Fighting Hepatitis C in a COVID-19 ecosystem. Public health policies are needed more than ever

Henrique Lopes, Ricardo Baptista‐Leite, Diogo Franco, Todor Kundurzhiev, Lyudmila Mateva, Dejan Jelev, Marieta Simonova

Journal of Gastrointestinal and Liver Diseases, 2020

3 citations

Abstract

Pregnancy in a liver transplant patient treated with everolimus and tacrolimusTo the Editor, We appreciated the paper regarding the quality of life in patients after liver transplantation (LT) by Domingos et al. [1], recently published in the Journal of Gastrointestinal and Liver Diseases.The authors reported a similar or superior quality of life in LT patients compared to the general population.Due to advances in immunology and transplant medicine, women with a history of LT could have successful pregnancies.However, data on pregnancy outcomes is still limited, especially for women with a history of liver graft failure, receiving the mammalian target of rapamycin (mTOR) inhibitors.Recently, many studies focused on everolimus benefits in the immunosuppression regimen after LT, which might be initiated early post-LT or in later monitoring phases, allowing the calcineurin inhibitor reduction [2].Published reports on pregnant women exposed to tacrolimus documented no increased risk of malformations, but data on pregnancy under everolimus is still relatively scarce [3, 4].We report a good clinical outcome of an unplanned pregnancy in a LT female patient aged 30 under everolimus and tacrolimus immunosuppression therapy.The patient had a successful LT at 20-year old for decompensated liver cirrhosis caused by Wilson disease.The recipient received tacrolimus as immunosuppressive therapy for 5 years with stable graft liver function.In 2016, at 25-years old, she had an unplanned…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free